Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis

Table 4 Adjusted HRs and 95%CIs for the association between hepatocellular carcinoma development and different variables

Criteria	HR	95%CI	P value
Rotterdam
Age	1.07	1.02-1.12	0.0041
Male sex	3.67	0.69-19.56	0.128
Cirrhosis	4.38	1.06-18.14	0.0411
APRI-r1 > 0.54	3.94	1.04-14.94	0.0431
Suboptimal treatment response	2.18	0.45-10.58	0.334
Paris I
Age	1.07	1.02-1.12	0.0031
Male sex	3.04	0.54-17.12	0.207
Albumin	0.94	0.80-1.09	0.386
Cirrhosis	4.37	1.07-17.75	0.0391
APRI-r1 > 0.54	3.92	1.06-14.54	0.0411
Suboptimal treatment response	1.7	0.41-7.03	0.466
Barcelona
Age	1.07	1.02-1.12	0.0051
Male sex	3.26	0.56-18.96	0.188
Albumin	0.93	0.80-1.07	0.307
Cirrhosis	4.44	1.06-18.56	0.0411
APRI-r1 > 0.54	4.47	1.26-15.93	0.0211
Suboptimal treatment response	1.22	0.33-4.49	0.768
Toronto
Age	1.07	1.02-1.13	0.0031
Male sex	3.22	0.56-18.50	0.19
Albumin	0.94	0.80-1.09	0.425
Cirrhosis	4.56	1.09-19.17	0.0381
APRI-r1 > 0.54	4.16	1.10-15.69	0.0361
Suboptimal treatment response	1.46	0.31-6.89	0.631

¹P-values < 0.05. The adjusted HR for suboptimal response was derived by multivariate analysis with other significant variables in Table 3 (age, male sex, cirrhosis and albumin) included. Separate multivariate analysis was performed for each criteria in defining suboptimal response. In the multivariate analyses, albumin was not included for the Rotterdam criteria. APRI-r1: AST/platelet ratio index at 1-year; HR: Hazard ratio.